Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Autonomix Medical, Inc. Common Stock Market Cap
The Autonomix Medical, Inc. Common Stock (AMIX) share price is expected to increase by 469.11% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered AMIX. Price targets range from $28 at the low end to $28 at the high end. The current analyst consensus for AMIX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assignedAMIX 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Autonomix Medical, Inc. Common Stock to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AMIX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AMIX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Ladenburg Thalmann | Buy | $1.4 | Initiates | Sep 3, 2024 |
When did it IPO
2024
Staff Count
5
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Bradley Hauser
Market Cap
$9.7M
In 2023, AMIX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AMIX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Autonomix Medical, Inc. (NASDAQ: AMIX) closed a public offering, raising approximately $10 million in gross proceeds, including a partial over-allotment option exercise.
Why It Matters - Autonomix Medical's $10 million capital raise enhances liquidity for growth initiatives, signaling confidence in future developments and potentially impacting stock valuation positively.
Fri, 22 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Autonomix Medical, Inc. (NASDAQ: AMIX) has priced a public offering of common stock and pre-funded warrant units, aiming for gross proceeds of about $9.0 million, excluding fees and expenses.
Why It Matters - The $9 million offering may dilute existing shares, impacting stock value. It indicates funding for growth initiatives, which could enhance future profitability and investor interest.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A clinical trial for pancreatic cancer pain shows 100% of initial responders eliminated opioid use within 4-6 weeks post-procedure, indicating promising preliminary results.
Why It Matters - The trial's success could indicate a breakthrough treatment for pancreatic cancer pain, potentially reducing opioid dependency and attracting investment in the biotech sector.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A Virtual Investor segment titled "What This Means" is available for access, providing insights that may be relevant for investors.
Why It Matters - The segment likely provides insights on market trends, company performance, or economic indicators, helping investors make informed decisions and adjust strategies accordingly.
Tue, 29 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Autonomix's RF ablation trial for pancreatic cancer pain reports early success with significant pain relief and opioid elimination in responding patients.
Why It Matters - Successful trial results for Autonomix’s RF ablation could lead to new treatment options, potentially boosting the company's stock value and attracting more investment in cancer therapies.
Mon, 28 Oct 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - U.S. stocks rose mid-session on Monday, with the Dow Jones index increasing by over 200 points.
Why It Matters - Rising U.S. stock indices indicate positive market sentiment, potentially boosting investor confidence and encouraging further investment activity.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
